Profiles of the molecular markers (P53,BCL-2, CD95, IPo38) as predictors of recurrence development in patients with malignant epithelial tumors of the eyelid skin
DOI:
https://doi.org/10.31288/oftalmolzh201326167Keywords:
malignant epithelial tumors of the eyelid skin, a monoclonal antibody (Bcl-2, p53, IPO38, CD95), the forecast of relapseAbstract
Introduction. To select the tactics impact on the tumor to identify predictors of treatment outcome. Substantial assistance in this study may have a malignant epithelial tumors (MET) of the eyelid skin at immunohistochemical level.
Purpose. Determine the information content of the expression of molecular markers of p53, Bcl-2, and CD95, IPO38 in tumor tissues to predict relapse in patients with MET eyelid skin.
Materials and methods. With the help of molecular markers (p53, Bcl-2, CD95, IPO38) conducted immunohistochemical studies of paraffin sections ofbiopsiesfrom 185 patients with eyelid skin MET (81 men and 104 women) aged 34 to 89years (me¬dian = 64,3, SD = 11.1) before treatment (radiotherapy + cryosurgery). To estimate the probability of recurrence developed a scoring scale on the basis ofwhich carry out the construction of the characteristic curve (ROC), found the optimal point of separation, calculated the area under the ROC curve and held its statistical evaluation.
Results. Found threshold values relative expression of molecular markers, which increases the probability of recurrent MET eyelid skin. Based on the thresholds found four markers developed a probabilistic model for prediction of recurrence MET eyelid skin, where the sensitivity was 97.1 %, specificity — 85.0 %. Conclusions. 1. When the index Bcl-2/CD95> 1.0 chances of relapse increase MET age of 21, 5 times. 2. If the total scoring risk assessment (relative values of p53, Bcl-2, CD95 and IPO38) recurrence MET eyelid skin is a threshold value for the sum OR> 76,2. The sensitivity of the model prediction was 97.1 % and specificity — 85.0 %.
References
1.Заридзе Д. Г., Алев Г. И., Альтштейн А. Д., Белицкий Г. А. Канцерогенез: [Руководство]. М.: Медицина, 2004. - 576 с.
2.Колесник А. П. Молекулярные маркеры прогрессирования колоректального рака / А. П. Колесник, И. Д. Паламарчук, А. М. Сидоренко // Онкология. - 2006. - № 1. - С.13-17.
3.Копнин Б. П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза / Б. П. Копнин // Биохимия. - 2000. - Т.65. - Вып.1. - С.5-33.
4.Пожарисский К. М. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний / К. М. Пожарисский, Е. Е. Леенман // Арх. пат. - 2000. - № 5. - С.3-11.
5.Реброва О. Ю. Статистический анализ медицинских данных / О. Ю. Реброва. М.: Медиа Сфера, 2003. - 312 с.
6.Ataman O. U. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer / O. U. Ataman, S. M. Bentzen, G. D. Wilson [et al]. // Eur. J. Cancer. - 2004. - V.40. - P.2734- 2741.https://doi.org/10.1016/j.ejca.2004.08.019
7.Barrett T. L. Immunohistochemical nuclear staining for p53, PCNA and Ki-67 in different histologic variants of basal cell carcinoma / T. L. Barrett, K. J. Smith, J. J. Hodge [et al]. // J. Am. Acad. Dermatol. - 1997. - V.37 - P.430- 437.https://doi.org/10.1016/S0190-9622(18)30744-8
8.D'Errico M. P53 mutations and chromosome instability in basal cell carcinomas developed at an early or late stage / M. D'Errico, A. S. Calcagnile, R. Corona [et al]. // Can¬cer. Res. - 1997. - V.57. - P.747- 752.
9.Rohbach J. M. Immunology and growth characteristics of ocular basal cell carcinoma / J. M. Rohbach, R. Stiemer, A. Mayer [et al]. // Graefe's Arch. Clin. Exp. Ophthal¬mol. - 2001. - V.239. - P.35- 40.https://doi.org/10.1007/s004170000221
Downloads
Published
Issue
Section
License
Copyright (c) 2013 И. А. Сафроненкова, Е. И. Драгомирецкая
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
